scholarly journals Late-onset nonlesional nondominant frontal lobe seizures presenting as ictal dyscalculia

2017 ◽  
Vol 33 (1) ◽  
pp. 52-54
Author(s):  
Meng-Tsang Hsieh ◽  
Ming-Chi Lai ◽  
Kao-Min Lin ◽  
Chin-Wei Huang
Epilepsia ◽  
2013 ◽  
Vol 55 (2) ◽  
pp. 264-277 ◽  
Author(s):  
Francesca Bonini ◽  
Aileen McGonigal ◽  
Agnès Trébuchon ◽  
Martine Gavaret ◽  
Fabrice Bartolomei ◽  
...  

CNS Spectrums ◽  
1999 ◽  
Vol 4 (9) ◽  
pp. 64-66,82 ◽  
Author(s):  
Bonnie J. Ramsey

AbstractAlthough psychotic symptoms are a recognized manifestation of epilepsy, these are more often associated with seizures of the temporal lobe type. While 10% of children with temporal lobe epilepsy develop a psychotic disorder by adulthood, the literature does not report any cases of psychotic disorders associated with frontal lobe seizures in children. This article presents a unique case of a girl whose frontal lobe seizures were associated with delusional psychotic symptoms. Once her seizure disorder was identified through electroencephalography (EEG) and appropriate anticonvulsant therapy was initiated, her associated psychotic symptoms resolved.


2018 ◽  
Vol 31 (5) ◽  
pp. 743-748 ◽  
Author(s):  
Flora T. Gossink ◽  
Everard Vijverberg ◽  
Welmoed Krudop ◽  
Philip Scheltens ◽  
Max L. Stek ◽  
...  

ABSTRACTA late onset frontal lobe syndrome (LOF) refers to a clinical syndrome with apathy, disinhibition, or stereotypical behavior arising in middle or late adulthood. Diagnostics are challenging, and both clinicians and patients need reliable predictors of progression to improve clinical guidance. In this longitudinal multicenter and genetically screened prospective study, 137 LOF patients with frontal behavior (FBI score≥11) and/or stereotypical behavior (SRI≥10) were included. Progression was defined as institutionalization, death, or progression of frontal or temporal atrophy at magnetic resonance imaging (MRI) after two years of follow up. Absence of progression at MRI in addition to stable or improved Mini Mental State Examination and Frontal Assessment Battery scores after two years was indicative for non-progression. The presence of stereotypy and a neuropsychological profile with executive deficits at baseline were found to be predictive for progression, while a history and family history with psychiatric disorders were predictors for non-progression. The combination of these clinical markers had a predictive value of 80.4% (p < 0.05). In patients presenting with late onset behavioral symptoms, an appraisal of the rate of deterioration can be made by detailed mapping of clinical symptoms. Distinction of progressive discourses from non-progressive or treatable conditions is to be gained.


2017 ◽  
Vol Volume 10 ◽  
pp. 163-166
Author(s):  
Domenico Chirchiglia ◽  
Attilio Della Torre ◽  
Domenico Murrone ◽  
Pasquale Chirchiglia ◽  
Rosa Marotta

Epilepsia ◽  
2012 ◽  
Vol 54 (2) ◽  
pp. 331-340 ◽  
Author(s):  
Dang Khoa Nguyen ◽  
Julie Tremblay ◽  
Philippe Pouliot ◽  
Phetsamone Vannasing ◽  
Olivia Florea ◽  
...  

2015 ◽  
Vol 41 (1-2) ◽  
pp. 16-26 ◽  
Author(s):  
Welmoed A. Krudop ◽  
Annemiek Dols ◽  
Cora J. Kerssens ◽  
Niels D. Prins ◽  
Christiane Möller ◽  
...  

Background: The criteria for behavioral variant frontotemporal dementia (bvFTD) incorporate MRI and [18F]-FDG-PET. Cerebrospinal fluid (CSF) analysis is merely advised for excluding Alzheimer's disease. Aims: We aimed to assess the impact of biomarkers on diagnostic certainty and contingent changes of bvFTD diagnosis within the clinically relevant neuropsychiatric differential diagnosis of subjects with a late-onset frontal lobe syndrome (LOF). Methods: We included 137 patients with LOF, aged 45-75 years, 72% males. Biomarker disclosure was considered contributing after any substantial difference in diagnostic certainty or a diagnostic change. Percentages of contributing biomarkers were compared between three major diagnostic groups (bvFTD, psychiatry, other neurological disorders). Certainty levels in stable diagnostic groups were compared to those with a diagnostic change. Results: Biomarkers contributed in 53, 60 and 41% of the LOF patients for MRI, [18F]-FDG-PET and CSF, respectively. Biomarkers changed the diagnosis in 14% of cases towards bvFTD and in 13% from bvFTD into an alternative. Those that changed had a lower level of a priori diagnostic certainty compared to stable diagnoses. Conclusion: Our study not only supports the widely accepted use of MRI and [18F]-FDG-PET in diagnosing or excluding bvFTD, but also shows that CSF biomarkers aid clinicians in the diagnostic process.


2005 ◽  
Vol 28 (3) ◽  
pp. 635-651 ◽  
Author(s):  
Barbara C. Jobst ◽  
Peter D. Williamson

Sign in / Sign up

Export Citation Format

Share Document